(PharmaNewsWire.Com, June 22, 2017 ) Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains.
Report Highlights
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline Target constitutes close to 28 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase SYK - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7, 3, 12 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology, Ophthalmology, Gastrointestinal, Hematological Disorders, Central Nervous System, Respiratory, Cardiovascular and Genito Urinary System And Sex Hormones which include indications Rheumatoid Arthritis, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia (CLL) , Allergic Conjunctivitis, Asthma, Atopic Dermatitis, Autoimmune Disorders, Chronic Lymphocytic Leukemia (CLL) , Cutaneous Lupus Erythematosus, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) , Inflammation, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL) , Relapsed Chronic Lymphocytic Leukemia (CLL) , Ulcerative Colitis, Acquired (Autoimmune) Hemolytic Anemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Allergies, Alzheimer's Disease, Anaphylactic Shock, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Blood Cancer, Chronic Urticaria Or Hives, Cutaneous T-Cell Lymphoma, Glomerulonephritis, Graft Versus Host Disease (GVHD) , Head And Neck Cancer Squamous Cell Carcinoma, Inflammatory Bowel Disease, Keratoconjunctivitis sicca (Dry Eye) , Leukemias, Lupus Erythematosus, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease) , Multiple Sclerosis, Non-Small Cell Lung Cancer, Post-Transplant Lymphoproliferative Disorder, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sicca Syndrome (Sjogren) , Skin Inflammation, Solid Tumor and Systemic Lupus Erythematosus.
Furthermore, this report also reviewsalso reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects - The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles AB Science SA Almirall SA Archer Pharmaceuticals Inc Asana BioSciences LLC Beijing Hanmi Pharmaceutical Co Ltd Celgene Corp Clevexel Pharma SAS F. Hoffmann-La Roche Ltd Fujifilm Corp Genosco Inc Gilead Sciences Inc GlaxoSmithKline Plc Hutchison China MediTech Ltd Japan Tobacco Inc Levolta Pharmaceuticals Inc Merck KGaA Millennium Pharmaceuticals Inc Portola Pharmaceuticals Inc Rigel Pharmaceuticals Inc Taiho Pharmaceutical Co Ltd TopiVert Ltd
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1) Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by AB Science SA, H1 2017 Pipeline by Almirall SA, H1 2017 Pipeline by Archer Pharmaceuticals Inc, H1 2017 Pipeline by Asana BioSciences LLC, H1 2017 Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2017 Pipeline by Celgene Corp, H1 2017 Pipeline by Clevexel Pharma SAS, H1 2017 Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Pipeline by Fujifilm Corp, H1 2017 Pipeline by Genosco Inc, H1 2017 Pipeline by Gilead Sciences Inc, H1 2017 Pipeline by GlaxoSmithKline Plc, H1 2017 Pipeline by Hutchison China MediTech Ltd, H1 2017 Pipeline by Japan Tobacco Inc, H1 2017 Pipeline by Levolta Pharmaceuticals Inc, H1 2017 Pipeline by Merck KGaA, H1 2017 Pipeline by Millennium Pharmaceuticals Inc, H1 2017 Pipeline by Portola Pharmaceuticals Inc, H1 2017 Pipeline by Rigel Pharmaceuticals Inc, H1 2017 Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017 Pipeline by TopiVert Ltd, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1) , H1 2017 Dormant Products, H1 2017 (Contd..2) , H1 2017 Discontinued Products, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: